Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy of two dose levels of UB-621 administration in reducing the HSV-2 genital shedding rate in patients with recurrent genital HSV-2 infection.


Clinical Trial Description

This is a 2-stage, randomized, double-blind, dose-ranging, multi-center phase 2 study designed to evaluate the efficacy, safety, and PK of UB-621 given at 2.5 or 5 mg/kg in adult subjects with recurrent genital HSV-2 infection. The study consists of 2 stages of enrollments, in which 40 subjects will be enrolled in the first stage and randomly assigned to receive placebo or UB-621 at 2.5 mg/kg in a 1:3 ratio into Cohort 1 at Bv6 (Day B57), and another 40 subjects will be enrolled in the second stage and randomly assigned to receive placebo or UB-621 at 5 mg/kg in a 1:3 ratio into Cohort 2 at Bv6 (Day B57) after review by the Data Safety Monitoring Committee (DSMC). The DSMC will review safety data after all subjects of Cohort 1 complete the visit Fv6 (Day F28) and make the recommendation whether to proceed with enrollment for Cohort 2. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03595995
Study type Interventional
Source United BioPharma
Contact Annie Lai
Phone +886-3-668-4800
Email annie.lai@unitedbiopharma.com
Status Not yet recruiting
Phase Phase 2
Start date June 1, 2023
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06033261 - A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes Phase 1/Phase 2
Completed NCT00362297 - Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2 Phase 4
Completed NCT01132729 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions N/A
Completed NCT01132716 - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions N/A
Completed NCT03831165 - Melatonin Effects on Genital Herpes in Brazilian Women Phase 4
Terminated NCT01658826 - Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes Phase 2
Completed NCT00262106 - Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection Phase 3
Completed NCT01346475 - Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2 Phase 4
Completed NCT01390805 - Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis) N/A
Terminated NCT03146403 - Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection Phase 2
Completed NCT03080961 - The VIBLOK SAfety and perFormancE Trial N/A
Completed NCT00306787 - Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes Phase 3
Completed NCT00231049 - Trial Evaluating Safety, Tolerability and Immune Response of AG-707 Phase 1
Completed NCT00495573 - HSV-2 Shedding Resolution After Acyclovir Treatment N/A
Completed NCT00477334 - Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients Phase 4
Completed NCT01281007 - Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes Phase 3
Completed NCT01112956 - Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2 N/A
Completed NCT00129818 - A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding Phase 4
Completed NCT00808405 - GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women N/A
Terminated NCT00495716 - Effect of HSV-2 Suppressive Therapy on Sexual Behavior Phase 4